21st May 2025 15:17
(Alliance News) - PureTech Health PLC on Wednesday said a trial of deupirfenidone demonstrated "strong and durable efficacy" in treating idiopathic pulmonary fibrosis.
PureTech is a London-based biotechnology company focused on developing therapies for serious diseases.
The company said deupirfenidone slowed lung function decline in people with IPF to the range expected of healthy older adults, in the phase 2b Elevate IPF trial.
It said new, preliminary open-label extension data supports the durability of this treatment effect over at least 52 weeks.
PureTech said the drug has demonstrated a statistically significant benefit compared to the placebo in delaying the progression of IPF.
"The IPF community has long needed therapies that can provide meaningful efficacy without compromising tolerability," said Chief Executive Officer Bharatt Chowrira.
"Data from our phase 2b trial and open-label extension study suggest that deupirfenidone may slow lung function decline in a way that more closely mirrors the natural aging process, and that this effect is durable. These data are quite remarkable and - to our knowledge - this level of efficacy has not been observed with other monotherapies.
"These findings further support our belief that deupirfenidone may offer a substantially differentiated treatment option for people living with IPF and support its potential to become a new standard of care," CEO Chowira added.
PureTech said it is targeting meeting with the US Food and Drug Administration by the end of the third quarter of 2025 to discuss the results of the trial and plan a potential registrational pathway.
The company added that it has the goal of starting a phase 3 trial by the end of the year.
Shares in PureTech Health were up 3.3% to 133.60 pence in London on Wednesday afternoon.
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
PureTech